{"id":171397,"date":"2026-09-21T22:19:25","date_gmt":"2026-09-21T22:19:25","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/171397\/"},"modified":"2026-09-21T22:19:25","modified_gmt":"2026-09-21T22:19:25","slug":"pharmalittle-novo-expanding-pipeline-alkermes-reports-adhd-data","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/171397\/","title":{"rendered":"Pharmalittle: Novo expanding pipeline, Alkermes reports ADHD data"},"content":{"rendered":"<p class=\"wp-block-paragraph\">Hello there and welcome to a new week. STAT reporter Andrew Joseph here in London filling in for Mr. Pharmalot for the day. Before we get to the headlines, an extra dose of encouragement to check out all the great pieces that STAT has to offer today, from Reed Jobs <a href=\"https:\/\/www.statnews.com\/2026\/09\/21\/nih-budget-double-100-billion-reed-jobs\/\" rel=\"nofollow noopener\" target=\"_blank\">opining on the NIH budget<\/a> to our new trust-in-science reporter Nick Florko <a href=\"https:\/\/www.statnews.com\/2026\/09\/21\/trust-in-science-nick-florko-on-understanding-growing-scientific-mistrust\/\" rel=\"nofollow noopener\" target=\"_blank\">outlining his own experience <\/a>grappling with, as he puts it, \u201chow frustrating it is to realize that modern medicine does not have all the answers.\u201d Now to those headlines. \u2026\u00a0<\/p>\n<p class=\"wp-block-paragraph\">Novo Nordisk is seeking to assure investors that it can regain its momentum in the coming years, outlining plans to expand its pipeline and find new products that it could sell more like consumer goods than traditional medicines, building off what\u2019s occurring with its obesity treatments, <a href=\"https:\/\/www.statnews.com\/2026\/09\/21\/novo-nordisk-capital-markets-day-obesity-strategy\/\" rel=\"nofollow noopener\" target=\"_blank\">STAT<\/a> shares. At the company\u2019s capital markets day in London, CEO Mike Doustdar said Novo would launch at least five multi-blockbusters by 2030 and deliver revenue growth on par with other major pharma firms. He also presented a strategy that involved investing more in disease areas outside diabetes and obesity and said the company \u201cwill be more active within business development,\u201d an acknowledgment of investors\u2019 concerns that Novo was too reliant on its landmark GLP-1 drugs and needed to develop other products.<\/p>\n<p class=\"wp-block-paragraph\">Drugs called orexin agonists have been hailed for their ability to treat rare sleep disorders, but with new data, Alkermes is showing for the first time that the new class of therapies may benefit people with ADHD, <a href=\"https:\/\/www.statnews.com\/2026\/09\/21\/alkermes-orexin-agonist-adhd-study\/\" rel=\"nofollow noopener\" target=\"_blank\">STAT<\/a> writes. In a randomized Phase 1 study, the company\u2019s new drug, called ALKS 7290, was well tolerated and showed a signal of efficacy. Participants in the study started with a median score of 39 on a diagnostic known as the Adult ADHD Investigator Symptom Rating Scale, indicating that they had moderate to severe symptoms. After two weeks, those taking a high dose of 50 milligrams of ALKS 7290 experienced a 19-point reduction on the scale, indicating that their symptoms had become mild.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/09\/1790029164_230_stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Hello there and welcome to a new week. STAT reporter Andrew Joseph here in London filling in for&hellip;\n","protected":false},"author":2,"featured_media":171398,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[272,6268,359],"class_list":["post-171397","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-novo-nordisk","tag-pharmalittle","tag-stat"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117311358275421362","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=171397"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/171397\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/171398"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=171397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=171397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=171397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}